<DOC>
	<DOCNO>NCT00044889</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . This single arm , open-label , Phase II study CLOFARABINE adult patient refractory relapse acute myelogenous leukemia ( AML ) . Qualified patient must refractory one two induction regimen , relapse &lt; one year date confirmation initial complete remission ( CR ) . There two phase study - Induction phase Consolidation phase .</brief_summary>
	<brief_title>Phase II Study Clofarabine Adult Patients With Refractory Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>note : For inclusion exclusion criterion , regimen define include Induction , Consolidation , Maintenance therapy . Diagnosis AML accord FAB classification Must eligible therapy higher curative potential , must first subsequent relapse and/or refractory A Karnofsky Performance Status ( KPS ) great equal 60 . If female childbearing potential , patient must negative serum urine pregnancy test within 7 day study enrollment . Men woman reproductive potential must use effective contraceptive method enrol study . Patients must contraceptive and/or fertility counsel prior enter study , i.e. , information sperm banking , etc . Signed , write informed consent . Ability comply study procedure followup examination . Adequate organ function indicate specific laboratory value ( define protocol ) , obtain within two week prior registration . Classified AML FAB M3 ( Acute Promyelocytic leukemia ) treat least 2 regimen ( retinoic acid contain regimen arsenic trioxide contain regimen ) consider study . note : For inclusion exclusion criterion , regimen define include Induction , Consolidation , Maintenance therapy . Received previous treatment CLOFARABINE . Received two previous induction regimen cycle treatment AML . Relapsed &gt; 1 year . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Are pregnant lactating . Have psychiatric disorder would interfere consent , study participation followup . Are receive chemotherapy corticosteroid . Patients must previous therapy least two week must recover acute toxicity previous therapy prior enrollment . Have severe concurrent disease . Have symptomatic CNS involvement . Have chronic myelogenous leukemia ( CML ) lymphoid blast crisis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CLO221</keyword>
	<keyword>clolar</keyword>
</DOC>